News & Media

Health Canada approves DispersinB® for Human Use

The DispersinB formulations are unique antibiofilm-antimicrobial and antibiotic free formulations that can be applied to the skin, scalp and hair. DispersinB skin care cream inhibits biofilm formation and also kills bacteria embedded in preformed microbial biofilm that cause recurring infections associated with atopic dermatitis including eczema, a chronic inflammatory condition of the skin that can affect individuals of all ages. It has both anti-inflammatory and anti-pruritic (anti-itching) effects. The skin cream can be used for relief of skin irritations associated redness, itching, dryness, scaling and redness due to eczema, insect bites, poison ivy, poison sumac, contact dermatitis, seborrheic dermatitis and psoriasis. DispersinB shampoo helps relieve itching and controls flaking caused by psoriasis or seborrhea, and dandruff. The global market for dermatology products is estimated at $4 billion per year.

The company continues to focus its resources and capital on the animal health sector at this time. The objective in animal health is to establish a portfolio of products and test market these products in order to build and strengthen our value proposition. Additional ongoing activities included in cementing this value proposition are pricing models, market messaging, manufacturing SOP’s and the development of new applications. Establishing a value proposition is a critical step in the scale up of our business regardless of whether a distribution strategy or a licensing strategy is ultimately taken. The company continues to be in a licensing option agreement with a global health care company for certain company assets in the animal health market. At this time the due diligence surrounding the option continues.

The company has been successful in developing a portfolio of products across multiple markets and there are a number of market opportunities to pursue. Current Health Canada approvals include:

Animal Health - StrixNB™ liquid water additive, StrixNB powder sachet, StrixNB bulk powder, StrixNB oral spray and DispersinB topical spray.

Human Health– DispersinB skin cream and shampoo for dermatology.

KBI Hard Surface Disinfectant (KBI) – Ready-to-use formulation and concentrate formulation with antimicrobial label claims.

Additional projects to initiate include Health Canada Low Risk Veterinary Health Products Program approval for DispersinB shampoo and StrixNB oral foam in the animal health market, enhancing the efficacy claims for DispersinB in human dermatological market and KBI disinfectant label expansion to include biofilm claims.

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

For more information, please contact: Gord Froehlich at:  ir@kanebiotech.com
 

Back

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.

Subscribe